Search results for PX-TA1323

Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade, ProteoGenix, PX-TA1323

Description of Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade General information on Anti-ganglioside GD2[Homo sapiens] (Dinutuximab) Monoclonal Antibody Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.